Biosimilars: A New Kind Of Innovation
Executive Summary
The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.
You may also be interested in...
Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.
Post Biocon, Pfizer Pushes Forward On Biosimilar MABs
Biosimilars pioneers face a steep learning curve and multiple surprises, as shown by Pfizer’s recent and expensive backtrack on its deal with India’s Biocon. But Pfizer says the setback has reaffirmed its strategy as it pushes ahead on its own with a monoclonal antibody program, led by a biosimilar rituximab.
Pfizer’s Biosimilar Program: A MAB Dash After Biocon Deal Ends
Following the breakup in March of its insulin biosimilars deal with Biocon, Pfizer confirms plans to develop monoclonal antibody biosimilars on its own, and has put its first candidate, rituximab, into Phase 1 testing.